Louise Abildgaard Steffensen

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al. · British Journal of Dermatology · 2020 · 595 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Targeting <scp>IL</scp>‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years

Emma Guttman‐Yassky, Kenji Kabashima, D. Staumont‐Sallé et al. · Allergy · 2024 · 53 citations · Full text

Medicine, Dermatology, Immunology +17

Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials

Eric L. Simpson, Andrew Pink, Andrew Blauvelt et al. · American Journal of Clinical Dermatology · 2023 · 29 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3)

Eric L. Simpson, Andreas Wollenberg, Weily Soong et al. · Annals of Allergy Asthma & Immunology · 2022 · 16 citations · Full text

Life Sciences, Dermatology, Pharmacotherapy +15

Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis

Stephan Weidinger, Anthony Bewley, Juan Francisco Silvestre et al. · British Journal of Dermatology · 2024 · 15 citations · Full text

Life Sciences, Dermatology, Pharmacotherapy +13